EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions

Merve Hazal Ser iD, Mason J Webb, Ugur Sener, Jian L Campian

Journal of Immunotherapy and Precision Oncology · 01.05.2024 · 7 (2) · 97-110

DOI: 10.36401/jipo-23-34 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunotherapy and Precision Oncology, online erschienen am 02.05.2024. Verfasst von Merve Hazal Ser und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most prevalent malignant tumor of the central nervous system. The prognosis of GBM is grim, with a median overall survival of 14.6 months and only 6.9% of patients surviving 5 years after the initial diagnosis. Despite poor outcomes, standard therapy of surgical resection, radiotherapy, chemotherapy, and tumor-treating fields has remained largely unchanged. The introduction of immune checkpoint inhibitors (ICI) has been a paradigm shift in oncology, with efficacy across a broad spectrum of cancer types. Nonetheless, investigations of ICIs in both newly diagnosed and recurrent GBM have thus far been disappointing. This lack of clinical benefit has been largely attributed to the highly immunosuppressive nature of GBM. However, immunotherapy still holds promise for the treatment of GBM, with combinatorial strategies offering hope for potentially overcoming these current limitations. In this review, we discuss the outcomes of clinical trials employing ICIs in patients with GBM. Afterward, we review ICI combination strategies and how these combinations may overcome the immunosuppressive microenvironment of GBM in the context of preclinical/clinical evidence and ongoing clinical trials.

Schlagwörter

Stichwörter der Autor:innen

ICIcombination therapyimmunotherapyoncolytic virotherapyvaccine therapy

Autor:innen und Institutionen

  • Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
  • Department of Neurology, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Merve Hazal Ser

Förderung

  • NCATS NIH HHS

Zitieren

APA

Ser, M. H., Webb, M. J., Sener, U., & Campian, J. L. (2024). Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions. Journal of Immunotherapy and Precision Oncology, 7(2), 97-110. https://doi.org/10.36401/jipo-23-34

Vancouver

Ser MH, Webb MJ, Sener U, Campian JL. Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions. Journal of Immunotherapy and Precision Oncology. 2024;7(2):97-110. doi:10.36401/jipo-23-34

BibTeX
@article{Ser2024,
  author = {Ser, Merve Hazal and Webb, Mason J and Sener, Ugur and Campian, Jian L},
  title = {Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2024},
  volume = {7},
  number = {2},
  pages = {97--110},
  doi = {10.36401/jipo-23-34}
}
Kostenlos starten →